Analyst Price Targets — MDWD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 9:18 pm | — | Industrial Alliance Securities | $22.00 | $14.56 | TheFly | MediWound price target lowered to $22 from $25 at Alliance Global |
| May 27, 2026 8:07 pm | Jay Olson | Oppenheimer | $32.00 | $14.33 | StreetInsider | MediWound Ltd (MDWD) PT Lowered to $32 at Oppenheimer |
| November 21, 2025 11:06 am | — | H.C. Wainwright | $36.00 | $16.86 | TheFly | MediWound price target raised to $36 from $31 at H.C. Wainwright |
| May 22, 2025 10:14 am | Swayampakula Ramakanth | H.C. Wainwright | $31.00 | $20.34 | TheFly | MediWound price target raised to $31 from $25 at H.C. Wainwright |
| February 28, 2025 1:57 pm | — | Craig-Hallum | $39.00 | $16.60 | TheFly | Craig-Hallum starts MediWound with Buy on EscharEx potential |
| October 11, 2024 6:38 am | Swayampakula Ramakanth | H.C. Wainwright | $28.00 | $16.92 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on MediWound Ltd (MDWD) |
| May 29, 2024 12:42 pm | Francois Brisebois | Oppenheimer | $36.00 | $16.01 | StreetInsider | Oppenheimer Reiterates Outperform Rating on MediWound Ltd (MDWD) |
| January 4, 2023 4:27 am | — | H.C. Wainwright | $23.00 | $13.29 | Benzinga | HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23 |
| December 30, 2022 9:10 am | — | Cowen & Co. | $25.00 | $13.49 | Benzinga | Cowen & Co. Maintains Outperform on MediWound, Adjusts Price Target to $25 - 1-for-7 Reverse Stock Split |
| December 22, 2022 8:33 am | — | Maxim Group | $25.00 | $11.01 | Benzinga | Maxim Group Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $25 |
Latest News for MDWD
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago.
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDWD.
U.S. House Trading
No House trades found for MDWD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.